Low oral bioavailability of poorly water-soluble drug candidates is currently one of the top challenges for drug development. Among enabling technologies available today, there is no “one size fits all” solution. In this webinar, industry experts will discuss the pros and cons of different drug delivery technologies and strategies for selecting the most suitable technology for any given molecule.
Spray-dried dispersion (SDD) has been successfully applied to many drug products in recent years. This webinar will introduce key SDD development considerations for identifying a stable formulation that enhances and sustains in-vivo drug solubility.
Dr. Sami Karaborni, Co-Founder, IHP Therapeutics
Dr. Karaborni is an expert in product and process development of new chemical entities (NCEs) and various dosage forms. Over his impressive 30-year career in the pharmaceutical and chemical industries, he served as VP of Development Operations, and Ex. Director of Preformulation & Formulation Development at XenoPort where he led multiple groups active in the areas of chemical, analytical, bioanalytical, formulation development, supply chain, and commercial manufacturing.
Prior to XenoPort, he was Director of Pre-clinical Development Technology, Director of Materials Characterization & Technology Assessment, and Director of Formulation Design and Characterization at Merck Research Labs (USA). In his early career, he was Sr. Research Engineer for the Royal Dutch Shell company (The Netherlands).
Dr. Karaborni is a member of the advisory board of the Surfactant Science series and inventor of more than 20 US published patents and patent applications and is the (co)author of more than 40 publications in international journalsMessage Presenter
Dr. Santipharp Panmai, Executive Director, Formulation R&D, STA Pharmaceutical, a WuXi AppTec company (WuXi STA)
Dr. Panmai joined STA Pharmaceutical, a WuXi AppTec company (WuXi STA) located in Shanghai, China in 2017. He is currently the Executive Director, Pharmaceutical Development Services leading a team responsible for formulation development and clinical trial materials of new chemical entities for global clients (US, Europe, and Asia).
Before joining WuXi STA, he worked at Merck in Pennsylvania and New Jersey USA for 18 years in the Pharmaceutical Sciences group. He has extensive experience in formulation development and material characterization. He led the development of Destrigo™, a fixed-dose combination, single tablet for HIV from formulation feasibility through to commercialization.
Dr. Panmai obtained his B.S. in Chemical Engineering from the University of California at Berkeley and Ph.D. in Chemical Engineering from Princeton University.Message Presenter
Who Should Attend?
- Formulation Scientist
- Drug Development Scientist
- Head of Formulation Development
- Head of New Drug Development
- Head of Pharmaceutical R&D
What You Will Learn
In this webinar, participants will learn:
- The pros and cons of different enabling technologies
- Key considerations to phase-appropriate enabling technology selection
- Best practices of SDD formulation development
WuXi STA, a WuXi AppTec Company
STA Pharmaceutical Co., Ltd., a subsidiary of WuXi AppTec (WuXi STA), is a leading pharmaceutical development and manufacturing capability and technology platform company serving the life sciences industry, with operations in China and the United States. As a premier Contract Development and Manufacturing Organization (CDMO), WuXi STA offers our worldwide partners efficient, flexible and high-quality solutions with integrated CMC (Chemical, Manufacturing, and Control) services for both drug substance and drug product from preclinical to commercial uses.
For more information, please visit: http://www.STApharma.com